In another study evaluating concomitant genetic alterations in KRAS, EGFR, ALK, ROS1 and BRAF in 3774 samples from NSCLC patients, the frequencies of single KRAS mutations and concomitant KRAS mutations were 8.0% and 1.1%, respectively, indicating that approximately 12% of KRAS-mutated NSCLC tumors had other driver mutations [84]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.